Asset Details
Do you wish to reserve the book?
Tofacitinib in Amyopathic Dermatomyositis–Associated Interstitial Lung Disease
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Tofacitinib in Amyopathic Dermatomyositis–Associated Interstitial Lung Disease
Do you wish to request the book?
Tofacitinib in Amyopathic Dermatomyositis–Associated Interstitial Lung Disease
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Tofacitinib in Amyopathic Dermatomyositis–Associated Interstitial Lung Disease
2019
Overview
The autoimmune disease amyopathic dermatomyositis–associated interstitial lung disease, which is related to anti–melanoma differentiation–associated protein 5 antibodies, is often rapidly progressive. Patients who received glucocorticoids and tofacitinib had improved survival.
Publisher
Massachusetts Medical Society
Subject
/ Dermatomyositis - complications
/ Female
/ Glucocorticoids - therapeutic use
/ Historically Controlled Study
/ Humans
/ Interferon-Induced Helicase, IFIH1 - immunology
/ Janus Kinase Inhibitors - therapeutic use
/ Kinases
/ Lung Diseases, Interstitial - drug therapy
/ Lung Diseases, Interstitial - etiology
/ Male
/ Melanoma
/ Methylprednisolone - therapeutic use
/ Piperidines - therapeutic use
